CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Summary

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.

Timeline

Start

2023-02-09

Primary completion

2024-08-31

Completion

2024-08-31

Drugs

Indications